Malignant transformation of mature cystic teratoma into undifferentiated carcinoma: A case report

Aryal, Vinayak; Maharjan, Rubina; Singh, Moushami; Marhatta, Adwait; Bajracharya, Amir; Dhakal, Hari Prasad

doi:10.1002/ccr3.5240

Cited by 3 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 There are two variants: cystic teratomas which are composed of fully mature elements and are usually benign and solid teratomas which are more likely to be malignant. 9 , 10 Primary retroperitoneal teratomas constitute 1 to 11% of retroperitoneal neoplasms and are most commonly found in neonates and in young adults. 2 They occur in female twice than male.…”

Section: Discussionmentioning

confidence: 99%

Extra‐gonadal mature teratoma: A case report of retroperitoneal location with a literature review

Mahjoubi

Kbir

Maatouk

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Extra‐gonadal mature teratoma: A case report of retroperitoneal location with a literature review

Mahjoubi

Kbir

Maatouk

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…8 Furthermore, several studies reported on different cancer components that coexist within the tumor. [9][10][11] These findings suggest that carcinomas arising from MCT may be a specifically highly heterogeneous tumor. Intratumor heterogeneity was observed in many tumors in cross-sectional carcinoma studies and implicated in tumor evolution, therapeutic resistance, and genomic instability.…”

Section: Introductionmentioning

confidence: 94%

“…Moreover, various histologic types of malignant tumors arise from MCT, including adenocarcinoma, carcinoid tumor, thyroid carcinoma, sarcoma, adenosquamous carcinoma, and melanoma 8 . Furthermore, several studies reported on different cancer components that coexist within the tumor 9–11 . These findings suggest that carcinomas arising from MCT may be a specifically highly heterogeneous tumor.…”

Section: Introductionmentioning

confidence: 99%

Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma

et al. 2023

View full text Add to dashboard Cite

Although the gross and microscopic features of squamous cell carcinoma arising from ovarian mature cystic teratoma (MCT‐SCC) vary from case to case, the spatial spreading of genomic alterations within the tumor remains unclear. To clarify the spatial genomic diversity in MCT‐SCCs, we performed whole‐exome sequencing by collecting 16 samples from histologically different parts of two MCT‐SCCs. Both cases showed histological diversity within the tumors (case 1: nonkeratinizing and keratinizing SCC and case 2: nonkeratinizing SCC and anaplastic carcinoma) and had different somatic mutation profiles by histological findings. Mutation signature analysis revealed a significantly enriched apolipoprotein B mRNA editing enzyme catalytic subunit (APOBEC) signature at all sites. Intriguingly, the spread of genomic alterations within the tumor and the clonal evolution patterns from nonmalignant epithelium to cancer sites differed between cases. TP53 mutation and copy number alterations were widespread at all sites, including the nonmalignant epithelium, in case 1. Keratinizing and nonkeratinizing SCCs were differentiated by the occurrence of unique somatic mutations from a common ancestral clone. In contrast, the nonmalignant epithelium showed almost no somatic mutations in case 2. TP53 mutation and the copy number alteration similarities were observed only in nonkeratinizing SCC samples. Nonkeratinizing SCC and anaplastic carcinoma shared almost no somatic mutations, suggesting that each locally and independently arose in the MCT. We demonstrated that two MCT‐SCCs with different histologic findings were highly heterogeneous tumors with clearly different clones associated with APOBEC‐mediated mutagenesis, suggesting the importance of evaluating intratumor histological and genetic heterogeneity among multiple sites of MCT‐SCC.

show abstract

“…Immunohistochemistry• Immunohistochemistry diagnosing several patients with suspected squamous cell carcinoma of the prostate (Keio University Hospital)[57], ovarian immature teratomas (University of California, San Francisco Medical Center)[51], and malignant transformation of mature cystic teratoma[58] …”

mentioning

confidence: 99%

“…Cont. Myeloid sarcoma (Armed Forces Medical College)[59], lung carcinoid (Precura Center)[60], and diffuse large B-cell lymphoma (Bach Mai Hospital) were diagnosed by flow cytometry[61] • MRI, MR, and computed tomography were used for the visual examination of patients with undiagnosed basaloid carcinoma of the prostate (Royal Marsden Hospital)[69], malignant transformation of mature cystic teratoma (Nepal Cancer Hospital and Research Center)[58], squamous cell carcinoma of the prostate (Keio University Hospital and Qingdao Municipal Hospital)[52,57] • Genome sequencing analysis diagnosed and detected cancerous sequences in patients with ovarian immature teratomas (University of California, San Francisco Medical Center)[51] and squamous cell carcinoma of the prostate (Qingdao Municipal Hospital)[52] …”

mentioning

confidence: 99%

An Overview of Advances in Rare Cancer Diagnosis and Treatment

Christyani,

Carswell,

Qin

et al. 2024

IJMS

View full text Add to dashboard Cite

Cancer stands as the leading global cause of mortality, with rare cancer comprising 230 distinct subtypes characterized by infrequent incidence. Despite the inherent challenges in addressing the diagnosis and treatment of rare cancers due to their low occurrence rates, several biomedical breakthroughs have led to significant advancement in both areas. This review provides a comprehensive overview of state-of-the-art diagnostic techniques that encompass new-generation sequencing and multi-omics, coupled with the integration of artificial intelligence and machine learning, that have revolutionized rare cancer diagnosis. In addition, this review highlights the latest innovations in rare cancer therapeutic options, comprising immunotherapy, targeted therapy, transplantation, and drug combination therapy, that have undergone clinical trials and significantly contribute to the tumor remission and overall survival of rare cancer patients. In this review, we summarize recent breakthroughs and insights in the understanding of rare cancer pathophysiology, diagnosis, and therapeutic modalities, as well as the challenges faced in the development of rare cancer diagnosis data interpretation and drug development.

show abstract

Malignant transformation of mature cystic teratoma into undifferentiated carcinoma: A case report

Cited by 3 publications

References 13 publications

Extra‐gonadal mature teratoma: A case report of retroperitoneal location with a literature review

Extra‐gonadal mature teratoma: A case report of retroperitoneal location with a literature review

Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma

An Overview of Advances in Rare Cancer Diagnosis and Treatment

Contact Info

Product

Resources

About